Indoor Biotechnologies’ SARS-CoV-2 Proteins and Simple T cell Test

Описание: Indoor Biotechnologies has a suite of SARS-CoV-2 proteins in various expression systems, as well as a rapid whole blood T cell test in development.

Indoor Biotechnologies has used its proven expertise in structural biology, protein expression and purification to manufacture a suite of recombinant SARS-CoV-2 proteins, including a full-length spike protein. These proteins have been engineered, optimized and expressed in both mammalian and bacterial expression systems. InBio® SARS-CoV-2 proteins are validated for purity by LC-MS/MS, and their IgG reactivity tested using COVID-19 positive patients’ sera by ELISA. These proteins are manufactured under an ISO 9001:2015 certified Quality Management System.

Indoor Biotechnologies has developed a rapid whole blood T cell test as part of an Innovate UK grant for assessment of vaccine or viral induced T cell response to SARS-CoV-2. Individuals exposed to SARS-CoV-2 may not produce long-lasting protective antibodies. T cell assays may be an important complement to COVID-19 diagnostic testing and vaccine development. Initial trials from InBio® show that the T cell test correlates with PCR and antibody responses and that the test can be used to monitor changes in T cell responses after vaccination.

Previously, virus specific T cell tests have been difficult to standardize and require specific knowledge/equipment, which presents a significant barrier for large scale, effective testing. The InBio® simple T cell test aims to break these barriers and is being optimized for easy implementation, enabling high throughput testing of COVID-19 T cell immunity.

Learning Objectives:
o Learn more on the available suite of SARS-CoV-2 proteins, including ELISA data comparing SARS-CoV-2 nucleocapsid RNA binding domain vs full-length spike proteins in determining vaccine efficacy.
o Learn more about the InBio® simple T cell test, including the development, milestones, and future goals.
o Understand how Indoor Biotechnologies’ SARS-CoV-2 resources can aid in COVID-19 research, diagnostics